The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma: The ESPAC-3 Periampullary Cancer Randomized Trial
Open accessAbstract
CONTEXT: Patients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas. OBJECTIVE: To determine whether adjuvant chemotherapy (fluorouracil or gemcitabine) provides improved overall survival following resection. DESIGN, SETTING, AND PATIENTS: The European Study Group for Pancreatic Cancer (ESPAC)-3 periampullary trial, an open-label, phase 3, randomized controlled trial (July 2000-May 2008) in 100 centers in Europe, Australia, Japan, and Canada. Of the 428 patients included in the primary analysis, 297 had ampullary, 96 had bile duct, and 35 had other cancers. INTERVENTIONS: One hundred forty-four patients were assigned to the observation group, 143 patients to receive 20 mg/m2 of folinic acid via intravenous bolus injection followed by 425 mg/m2 of fluorouracil via intravenous bolus injection administered 1 to 5 days every 28 days, and 141 patients to receive 1000 mg/m2 of intravenous infusion of gemcitabine once a week for 3 of every 4 weeks for 6 months. MAIN OUTCOME MEASURES: The primary outcome measure was overall survival with chemotherapy vs no chemotherapy; secondary measures were chemotherapy type, toxic effects, progression-free survival, and quality of life. RESULTS: Eighty-eight patients (61%) in the observation group, 83 (58%) in the fluorouracil plus folinic acid group, and 73 (52%) in the gemcitabine group died. In the observation group, the median survival was 35.2 months (95%% CI, 27.2-43.0 months) and was 43.1 (95%, CI, 34.0-56.0) in the 2 chemotherapy groups (hazard ratio, 0.86; (95% CI, 0.66-1.11; χ2 = 1.33; P = .25). After adjusting for independent prognostic variables of age, bile duct cancer, poor tumor differentiation, and positive lymph nodes and after conducting multiple regression analysis, the hazard ratio for chemotherapy compared with observation was 0.75 (95% CI, 0.57-0.98; Wald χ2 = 4.53, P = .03). CONCLUSIONS: Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was not associated with a significant survival benefit in the primary analysis; however, multivariable analysis adjusting for prognostic variables demonstrated a statistically significant survival benefit associated with adjuvant chemotherapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00058201.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Self-citationAsymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Self-citationNeoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Self-citationKlinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00006 · Cited by 1,286
Neoptolemos, J., Dunn, J., Stocken, D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06651-x · Cited by 1,111
Self-citationResected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up
Riall, T. S., Cameron, J. L., Lillemoe, K. D., Winter, J. M., Campbell, K. A., Hruban, R. H., Chang, D., & Yeo, C. J. (2006) · Surgery · doi:10.1016/j.surg.2006.04.006 · Cited by 246
Westgaard, A., Tafjord, S., Farstad, I. N., Cvancarova, M., Eide, T. J., Mathisen, O., Clausen, O. P. F., & Gladhaug, I. P. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-170 · Cited by 244
Riall, T. S., Cameron, J. L., Lillemoe, K. D., Campbell, K. A., Sauter, P. K., Coleman, J., Abrams, R. A., Laheru, D., Hruban, R. H., & Yeo, C. J. (2005) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2005.08.034 · Cited by 219
Predictors of Survival in Periampullary Cancers Following Pancreaticoduodenectomy
Hatzaras, I., George, N., Muscarella, P., Melvin, W. S., Ellison, E. C., & Bloomston, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0883-9 · Cited by 158
A Surgical and Pathological Based Classification of Resective Treatment of Pancreatic Cancer
Pedrazzoli, S., Beger, H. G., Obertop, H., Andrén‐Sandberg, Å., Fernández‐Cruz, L., Henne‐Bruns, D., Lüttges, J., & Neoptolemos, J. P. (1999) · Digestive Surgery · doi:10.1159/000018744 · Cited by 142
Self-citationSmith, R. A., Ghaneh, P., Sutton, R., Raraty, M. G. T., Campbell, F., & Neoptolemos, J. P. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0554-3 · Cited by 142
Self-citationHenson, D. E., Schwartz, A. M., Nsouli, H. H., & Albores‐Saavedra, J. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.1.67 · Cited by 83
Westgaard, A., Schjølberg, A. R., Cvancarova, M., Eide, T. J., Clausen, O. P. F., & Gladhaug, I. P. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03227.x · Cited by 62
Schönleben, F., Qiu, W., Allendorf, J., Chabot, J. A., Remotti, H. E., & Su, G. H. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0917-4 · Cited by 59
Cited by
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., Löhr, J.-M., Neoptolemos, J., Real, F. X., Van Laethem, J.-L., & Heinemann, V. (2015) · Pancreatology · doi:10.1016/j.pan.2014.10.001 · Cited by 509
Self-citationMultidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Intrahepatic Cholangiocarcinoma: expert consensus statement
Weber, S. M., Ribero, D., O'Reilly, E. M., Kokudo, N., Miyazaki, M., & Pawlik, T. M. (2015) · HPB · doi:10.1111/hpb.12441 · Cited by 472
Incio, J., Liu, H., Suboj, P., Chin, S. M., Chen, I. X., Pinter, M., Ng, M. R., Nia, H. T., Grahovac, J., Kao, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1177 · Cited by 456
Metadata
- Authors
- Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., McDonald, A. C., Carter, R., Tebbutt, N. C., Dervenis, C., Smith, D., Glimelius, B., Charnley, R. M., Lacaine, F., Scarfe, A. G., Middleton, M. R., Anthoney, A., Ghaneh, P., Halloran, C. M., Lerch, M. M., Oláh, A., Rawcliffe, C. L., Verbeke, C. S., Campbell, F., Büchler, M. W., & European Study Group for Pancreatic Cancer, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-07-11
- Volume
- 308
- Issue
- 2
- Pages
- 147
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2000085538
- Cited by
- 597
- References
- 18
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.